Posted by Michael Wonder on 20 Aug 2022
Kapruvia approved in Switzerland with additional regulatory decisions expected in H2, 2022
19 August 2022 - Regulatory decisions in Australia and Singapore expected by the end of 2022.
Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics today announced that they have received approval for Kapruvia from the Swiss Agency for Therapeutic Products (Swissmedic).
